Page last updated: 2024-08-21

isoxazoles and celecoxib

isoxazoles has been researched along with celecoxib in 97 studies

Research

Studies (97)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (1.03)18.2507
2000's72 (74.23)29.6817
2010's19 (19.59)24.3611
2020's5 (5.15)2.80

Authors

AuthorsStudies
Arriola, ER; Lee, NP1
Infante, R; Lahita, RG1
Chong, BS; Lowder, DM; Luong, BT1
Simon, LS; Yocum, D1
Gierse, JK; Isakson, PC; Kiefer, JR; Koboldt, CM; Kurumbail, RG; Moreland, KT; Seibert, K; Walker, MC1
Wasko, MC; Wildy, KS1
Ouellet, M; Percival, MD; Riendeau, D1
FitzGerald, GA2
Hardy, KJ; McMurray, RW1
Hayes, EC; Rock, JA1
Rowbotham, DJ1
Gierse, JK; Hood, WF; Isakson, PC; Kiefer, JR; Kurumbail, RG; Monahan, JB; Seibert, K1
Carter, J; Gierse, J; Hood, B; Isakson, P; Kiefer, J; Koboldt, C; Kurumbail, R; Marnett, L; Monahan, J; Moreland, K; Pawlitz, J; Pierce, J; Rowlinson, S; Seibert, K; Stegeman, R; Stevens, A; Talley, J; Walker, M1
Boehncke, WH; Gibbs, BF1
Laskin, B; Pashos, C; Peña, B; Stephens, J; Wong, J1
Burian, M; Geisslinger, G1
Blumenthal, M; Chen, TC; Kardosh, A; Schönthal, AH; Wang, WJ1
Casini, A; Heine, A; Klebe, G; Kuhn, D; Scozzafava, A; Supuran, CT; Weber, A1
Møiniche, S; Rømsing, J1
Chan, VS1
Benoit, V; de Leval, X; Dogné, JM; Frederich, M; Julémont, F; Pirotte, B1
Boggie, DT; Delattre, ML; Morreale, AP; Plowman, BK; Schaefer, MG; Tran, F1
Dahlborg, R; Day, CA; Jacob, RF; Mason, RP; Walter, MF; Weng, Y1
Topol, EJ1
Meena, S; Nagaraju, D; Rao, AR; Rao, RN1
Furberg, CD; Psaty, BM1
Drazen, JM1
Wadman, M2
Couzin, J1
Okie, S1
Romanovsky, AA1
Cotter, J; Wooltorton, E1
Vanchieri, C1
Albini, A; Noonan, DM1
Hochberg, MC1
Mullangi, R; Pavan Kumar, VV; Ramani, AV; Srinivas, NR; Vinu, MC1
Epstein, RA1
Cohen, JS1
Cantilena, LR; Carlsson, U; Hammarström, P; Knudsen, JF; Sokol, GH1
Bonnel, R; Brinker, A; Governale, L; Karwoski, C; La Grenade, L; Lee, L; Weaver, J1
Meechan, J1
Epstein, J; Klasser, GD1
D'Ambrosio, K; De Simone, G; Di Fiore, A; Pedone, C; Scozzafava, A; Supuran, CT1
Gherardi, CR1
Fraunfelder, FW; Mehelas, TJ; Solomon, J1
Dogné, JM; Hanson, J; Pratico, D; Supuran, C1
Ciddi, V; Keshetty, S; Molmoori, V; Venisetty, RK1
Bhatia, S; Seedher, N1
Furberg, CD1
Bohn, L; Sadée, W1
Macrì, R; Manfredi, C1
Abdalla, H; Buckley, E; Butler, M; Iohom, G; Larney, V; O'Brien, J; Shorten, GD; Szarvas, S1
Deray, G; Montalescot, G; Sibilia, J1
Deray, G; Héloire, F; Valat, JP1
Jugdutt, BI1
Macedo, GM; Medeiros, BA; Nobre-e-Souza, MA; Palheta-Junior, RC; Santos, AA; Santos, CL; Souza, MH; Troncon, LE1
Gajraj, NM1
Tabrizchi, R1
Ashcroft, DM; Chen, LC1
Bombardier, C; Coombs, JH; Copley-Merriman, C; Evans, C; Katz, N; Markman, J; Robbins, J; Simon, LS; West, C1
Arguelles, J; Cobo, J; Costales, M; de Carlos, F; Garcia, MA; Perillan, C; Vijande, M1
Chen, E; Li, C; Maguluri, S; Recchia, FM1
DeAngelis, CD; Thornton, JP1
Blum, D; Cunnington, M; Funk, MJ; Mander, A; Qizilbash, N; Webb, D; Weil, J1
Boutary, M; Dorr, LD; Long, WT; Raya, J; Sirianni, LE1
Fujikawa, Y; Itonaga, I; Kawashima, M; Takita, C; Tsumura, H1
Simon, LS; White, WB1
Mateos, JL1
Elliott, WJ1
Intapan, T; Ittichaikulthol, W; Kositchaiwat, C; Prachanpanich, N1
Ashok, V; Dash, C; Rohan, TE; Sprafka, JM; Terry, PD1
Honjo, H; Iwamoto, K; Uwai, Y1
Dávila, I; González, A; Laffond, E; Moreno, E; Muñoz-Bellido, F; Ponce, V1
Baber, C; McDonnell, NJ; Nathan, EA; Paech, MJ; Sinha, A1
Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y1
Li, J; Li, N; Peng, N; Yang, X1
Balbontín-Ayala, F; Cañigral, A; Carlos, Fd; Cobo, T; Fernández-González, FJ; Fernández-Vázquez, JP; Gonzalo-Orden, JM; Sánchez-Lasheras, F; Vega, JA1
Hansen, SH; Skonberg, C; Syed, M1
Supuran, CT1
Katchamart, W; Suwanawiboon, B; Tantayakom, P; Teerawattananon, C1
Bian, Y; Feng, B; Jiang, J; Lin, J; Pei, F; Shen, B; Sun, T; Wang, W; Weng, X; Yan, S; Zhang, M; Zhuang, Q1
Filippini-de Moor, GP; Steegers, MA; van Helmond, N; Vissers, KC; Wilder-Smith, OH1
Cheng, L; Long, HT; Sun, BH; Zhao, SS; Zhu, Y1
Cai, W; Fan, J; Tang, J; Yao, Y; Yin, G; Zhou, W1
Pei, F; Shen, B; Si, H; Weng, X; Wu, Y; Yang, T; Zeng, Y1
Cooper, AR; Dileep Kumar, JS; Mann, JJ; Matthew, J; Parsey, RV; Prabhakaran, J; Rubin-Falcone, H; Simpson, NR; Underwood, M; Zanderigo, F1
Bian, Y; Dong, Y; Fan, Y; Feng, B; Gao, N; Jin, J; Li, Y; Lin, J; Pei, F; Peng, H; Qian, W; Shen, B; Sun, T; Tao, L; Wang, W; Weng, X; Yan, S; Zhang, M; Zhuang, Q1
Huang, L; Huang, Z; Jia, X; Liu, L; Ma, X; Tang, C; Wan, X; Wang, R; Zhang, M1
Hu, XG; Jiang, W; Pang, JY; Wan, C; Zhang, XW1
Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K1
Chaibhuddanugul, N; Laoruengthana, A; Malisorn, S; Pongpirul, K; Rattanaprichavej, P; Tangsripong, P1

Reviews

27 review(s) available for isoxazoles and celecoxib

ArticleYear
Treatment advances in rheumatoid arthritis.
    The Western journal of medicine, 1999, Volume: 170, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Isoxazoles; Leflunomide; Male; Prognosis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Treatment Outcome

1999
Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs.
    Geriatrics, 2000, Volume: 55, Issue:3

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Male; Middle Aged; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides; Sulfones

2000
Treatment options for rheumatoid arthritis: celecoxib, leflunomide, etanercept, and infliximab.
    The Annals of pharmacotherapy, 2000, Volume: 34, Issue:6

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Drug Interactions; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Male; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides

2000
New and future drug therapies for rheumatoid arthritis.
    Rheumatology (Oxford, England), 2000, Volume: 39 Suppl 1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; CD40 Antigens; Celecoxib; Etanercept; Forecasting; Humans; Immunoglobulin G; Infliximab; Isoxazoles; Leflunomide; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfonamides

2000
Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.
    Hand clinics, 2001, Volume: 17, Issue:2

    Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhibitors; Digestive System; Etanercept; Glucocorticoids; Humans; Hydroxychloroquine; Immunoglobulin G; Infliximab; Isoxazoles; Lactones; Leflunomide; Methotrexate; Osteoarthritis; Pyrazoles; Receptors, Tumor Necrosis Factor; Sulfasalazine; Sulfonamides; Sulfones

2001
Cox-2 inhibitors: today and tomorrow.
    The American journal of the medical sciences, 2002, Volume: 323, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Research; Sulfonamides; Sulfones

2002
COX-2 inhibitors and their role in gynecology.
    Obstetrical & gynecological survey, 2002, Volume: 57, Issue:11

    Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Administration Schedule; Dysmenorrhea; Endometriosis; Female; Genital Diseases, Female; Humans; Infertility, Female; Isoenzymes; Isoxazoles; Labor, Obstetric; Membrane Proteins; Menorrhagia; Menstrual Cycle; Ovary; Ovulation; Pain; Polycystic Ovary Syndrome; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides

2002
COX-2-selective inhibitors: clinical relevance in surgical and acute pain.
    European journal of anaesthesiology. Supplement, 2002, Volume: 25

    Topics: Acute Disease; Analgesics; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Pain; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides

2002
The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors.
    Rheumatology (Oxford, England), 2003, Volume: 42 Suppl 3

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost of Illness; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pain, Postoperative; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quality of Life; Sulfonamides; Sulfones; Treatment Outcome

2003
[Clinical pharmacology of the selective COX-2 inhibitors].
    Der Orthopade, 2003, Volume: 32, Issue:12

    Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones

2003
A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain.
    Acta anaesthesiologica Scandinavica, 2004, Volume: 48, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Pain Measurement; Pain, Postoperative; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones; Treatment Outcome

2004
A mechanistic perspective on the specificity and extent of COX-2 inhibition in pregnancy.
    Drug safety, 2004, Volume: 27, Issue:7

    Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Female; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Pregnancy; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones

2004
First and second generations of COX-2 selective inhibitors.
    Mini reviews in medicinal chemistry, 2004, Volume: 4, Issue:6

    Topics: Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sulfonamides; Sulfones

2004
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
    Current topics in medicinal chemistry, 2005, Volume: 5, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome

2005
Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
    Journal (Canadian Dental Association), 2005, Volume: 71, Issue:8

    Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Peptic Ulcer; Pyrazoles; Sulfonamides; Sulfones; Toothache

2005
Coxibs and cardiovascular side-effects: from light to shadow.
    Current pharmaceutical design, 2006, Volume: 12, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Epoprostenol; Humans; Isoxazoles; Lactones; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Sulfones; Thromboxane A2

2006
[What do we know about the cardiovascular toxicity of the NSAIDs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:9 Spec No

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Diclofenac; Edema; Heart Failure; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Odds Ratio; Placebos; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors

2006
COX-2 inhibitors celecoxib and parecoxib: valuable options for postoperative pain management.
    Current topics in medicinal chemistry, 2007, Volume: 7, Issue:3

    Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Pain, Postoperative; Pyrazoles; Sulfonamides; Treatment Outcome

2007
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Pharmacoepidemiology and drug safety, 2007, Volume: 16, Issue:7

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones

2007
COX-2 selective inhibitors and heart health.
    Postgraduate medicine, 2005, Volume: 117, Issue:1 Suppl

    Topics: Adult; Cardiovascular Diseases; Celecoxib; Child; Cyclooxygenase 2 Inhibitors; Humans; Hypertension; Isoxazoles; Lactones; Meta-Analysis as Topic; Prospective Studies; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Sulfones

2005
[Selective inhibitors of cyclooxygenase-2 (COX-2), celecoxib and parecoxib: a systematic review].
    Drugs of today (Barcelona, Spain : 1998), 2010, Volume: 46 Suppl A

    Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Routes; Evidence-Based Medicine; Humans; Inflammation; Isoxazoles; Pain; Pain Measurement; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Treatment Outcome

2010
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
    Current hypertension reports, 2010, Volume: 12, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones

2010
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
    The Cochrane database of systematic reviews, 2014, Oct-23, Issue:10

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones

2014
Experimental evidence of pharmacological management of anchorage in Orthodontics: A systematic review.
    Dental press journal of orthodontics, 2015, Volume: 20, Issue:5

    Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Bone Remodeling; Celecoxib; Clodronic Acid; Diclofenac; Diphosphonates; Humans; Imidazoles; Interferon-gamma; Isoxazoles; Lactones; Mice; Orthodontic Anchorage Procedures; Osteoclasts; Osteoprotegerin; Pamidronate; Rats; Resveratrol; Stilbenes; Sulfones; Tooth Mobility; Tooth Movement Techniques; Zoledronic Acid

2015
Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.
    Expert opinion on drug metabolism & toxicology, 2016, Volume: 12, Issue:4

    Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Antibodies, Monoclonal; Anticonvulsants; Antineoplastic Agents; Benzodiazepines; Carbonic Anhydrase Inhibitors; Celecoxib; Clinical Trials as Topic; Contraindications; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fructose; Humans; Isoxazoles; Methazolamide; Phenobarbital; Sulfanilamide; Sulfanilamides; Sulfonamides; Sulfonic Acids; Thiazines; Thiophenes; Topiramate; Zonisamide

2016
Risk of perioperative bleeding related to highly selective cyclooxygenase-2 inhibitors: A systematic review and meta-analysis.
    Seminars in arthritis and rheumatism, 2017, Volume: 46, Issue:4

    Topics: Blood Loss, Surgical; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Isoxazoles; Postoperative Hemorrhage; Pyridines; Risk Factors; Sulfones

2017

Trials

14 trial(s) available for isoxazoles and celecoxib

ArticleYear
Therapeutic interchange involving replacement of rofecoxib or celecoxib with valdecoxib.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Jul-01, Volume: 61, Issue:13

    Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Celecoxib; Chronic Disease; Cost Savings; Cyclooxygenase 2; Drug Utilization Review; Endpoint Determination; Female; Hospitals, Veterans; Humans; Isoenzymes; Isoxazoles; Lactones; Male; Membrane Proteins; Osteoarthritis; Pain; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Therapeutic Equivalency

2004
COX-2 inhibitors and pain after oral surgery - pertinent papers 2002-2003.
    The British journal of oral & maxillofacial surgery, 2006, Volume: 44, Issue:2

    Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Ibuprofen; Injections, Intravenous; Isoxazoles; Lactones; Pain, Postoperative; Preanesthetic Medication; Prodrugs; Pyrazoles; Sulfonamides; Sulfones; Tooth Extraction

2006
Determination of valdecoxib in serum using a HPLC-diode array detector and its application in a pharmacokinetic study.
    Die Pharmazie, 2006, Volume: 61, Issue:3

    Topics: Adult; Area Under Curve; Celecoxib; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Half-Life; Humans; Isoxazoles; Male; Pyrazoles; Sulfonamides

2006
The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery.
    Anesthesia and analgesia, 2006, Volume: 103, Issue:4

    Topics: Acetaminophen; Adult; Aged; Analgesia; Anxiety; Breast Neoplasms; Bupivacaine; Celecoxib; Chronic Disease; Depression; Dextropropoxyphene; Diclofenac; Female; Humans; Isoxazoles; Mastectomy; Middle Aged; Morphine; Nerve Block; Nitric Oxide; Nociceptors; Pain Measurement; Pain, Postoperative; Pyrazoles; Sulfonamides

2006
Multimodal analgesia without parenteral narcotics for total knee arthroplasty.
    The Journal of arthroplasty, 2008, Volume: 23, Issue:4

    Topics: Administration, Oral; Amides; Analgesia, Epidural; Analgesia, Patient-Controlled; Analgesics; Analgesics, Opioid; Anesthetics, Local; Arthroplasty, Replacement, Knee; Aspirin; Catheters, Indwelling; Celecoxib; Drug Administration Schedule; Drug Therapy, Combination; Femoral Nerve; Hip Joint; Humans; Injections, Intra-Articular; Isoxazoles; Ketorolac; Nerve Block; Pain Measurement; Pain, Postoperative; Prospective Studies; Pyrazoles; Ropivacaine; Sulfonamides

2008
The post-operative analgesic efficacy of celecoxib compared with placebo and parecoxib after total hip or knee arthroplasty.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010, Volume: 93, Issue:8

    Topics: Administration, Oral; Adolescent; Adult; Aged; Analgesia; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase Inhibitors; Female; Humans; Isoxazoles; Male; Middle Aged; Pain, Postoperative; Postoperative Period; Pyrazoles; Sulfonamides; Treatment Outcome; Young Adult

2010
A randomised controlled trial of parecoxib, celecoxib and paracetamol as adjuncts to patient-controlled epidural analgesia after caesarean delivery.
    Anaesthesia and intensive care, 2014, Volume: 42, Issue:1

    Topics: Acetaminophen; Adult; Analgesia, Epidural; Analgesia, Obstetrical; Analgesia, Patient-Controlled; Analgesics, Non-Narcotic; Celecoxib; Cesarean Section; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Isoxazoles; Pregnancy; Pyrazoles; Sulfonamides

2014
Effect of cyclooxygenase-2-specific inhibitors on postoperative analgesia after major open abdominal surgery.
    Pain management nursing : official journal of the American Society of Pain Management Nurses, 2015, Volume: 16, Issue:3

    Topics: Abdomen; Analgesia, Patient-Controlled; Analgesics, Opioid; Analysis of Variance; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Elective Surgical Procedures; Female; Humans; Isoxazoles; Male; Middle Aged; Morphine; Pain Measurement; Pain, Postoperative; Prospective Studies; Tramadol

2015
Efficacy and safety of Postoperative Intravenous Parecoxib sodium Followed by ORal CElecoxib (PIPFORCE) post-total knee arthroplasty in patients with osteoarthritis: a study protocol for a multicentre, double-blind, parallel-group trial.
    BMJ open, 2016, 09-08, Volume: 6, Issue:9

    Topics: Administration, Oral; Arthroplasty, Replacement, Knee; Celecoxib; China; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, Combination; Humans; Injections, Intravenous; Isoxazoles; Osteoarthritis; Pain, Postoperative; Postoperative Care; Research Design; Treatment Outcome

2016
Hyperalgesia and Persistent Pain after Breast Cancer Surgery: A Prospective Randomized Controlled Trial with Perioperative COX-2 Inhibition.
    PloS one, 2016, Volume: 11, Issue:12

    Topics: Adult; Aged; Breast Neoplasms; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Humans; Hyperalgesia; Isoxazoles; Mastectomy; Mastectomy, Segmental; Middle Aged; Pain Measurement; Pain Threshold; Pain, Postoperative; Perioperative Period; Prospective Studies; Quality of Life; Surveys and Questionnaires; Treatment Outcome

2016
Application of a buprenorphine transdermal patch for the perioperative analgesia in patients who underwent simple lumbar discectomy.
    Medicine, 2017, Volume: 96, Issue:20

    Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Analgesics, Opioid; Buprenorphine; Celecoxib; Cyclooxygenase 2 Inhibitors; Diskectomy; Female; Humans; Isoxazoles; Lumbar Vertebrae; Male; Middle Aged; Pain Measurement; Pain, Postoperative; Patient Satisfaction; Perioperative Care; Tramadol; Transdermal Patch; Treatment Outcome

2017
[EFFICACY OF SEQUENTIAL TREATMENT WITH ADDUCTOR CANAL NERVE BLOCK AND CYCLOOXYGENASE 2 SELECTIVE INHIBITOR AFTER TOTAL KNEE ARTHROPLASTY].
    Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery, 2016, Sep-08, Volume: 30, Issue:9

    Topics: Analgesics, Opioid; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Knee Joint; Morphine; Nerve Block; Operative Time; Osteoarthritis; Pain, Postoperative; Postoperative Period; Range of Motion, Articular; Treatment Outcome

2016
Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial.
    BMJ open, 2020, 01-09, Volume: 10, Issue:1

    Topics: Administration, Intravenous; Administration, Oral; Aged; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Female; Follow-Up Studies; Humans; Isoxazoles; Male; Osteoarthritis, Knee; Pain, Postoperative; Postoperative Care; Retrospective Studies; Treatment Outcome

2020
Prevention of Severe Acute Pancreatitis With Cyclooxygenase-2 Inhibitors: A Randomized Controlled Clinical Trial.
    The American journal of gastroenterology, 2020, Volume: 115, Issue:3

    Topics: Administration, Oral; Adolescent; Adult; Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Injections, Intravenous; Isoxazoles; Male; Middle Aged; Pancreatitis; Prospective Studies; Severity of Illness Index; Treatment Outcome; Young Adult

2020

Other Studies

56 other study(ies) available for isoxazoles and celecoxib

ArticleYear
A three-step kinetic mechanism for selective inhibition of cyclo-oxygenase-2 by diarylheterocyclic inhibitors.
    The Biochemical journal, 2001, Aug-01, Volume: 357, Issue:Pt 3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding, Competitive; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Isoxazoles; Kinetics; Meloxicam; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sheep; Sulfonamides; Thiazines; Thiazoles

2001
A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
    Proceedings of the National Academy of Sciences of the United States of America, 2001, Dec-04, Volume: 98, Issue:25

    Topics: Acetylation; Animals; Aspirin; Blood Platelets; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Etoricoxib; Humans; Ibuprofen; In Vitro Techniques; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Sheep; Sulfonamides; Sulfones

2001
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach.
    The American journal of cardiology, 2002, Mar-21, Volume: 89, Issue:6A

    Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular System; Celecoxib; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Isoxazoles; Lactones; Male; Pyrazoles; Sulfonamides; Sulfones

2002
Characterization of celecoxib and valdecoxib binding to cyclooxygenase.
    Molecular pharmacology, 2003, Volume: 63, Issue:4

    Topics: Animals; Binding Sites; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Isoenzymes; Isoxazoles; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recombinant Proteins; Sheep; Sulfonamides; Tritium

2003
Mechanism of inhibition of novel COX-2 inhibitors.
    Advances in experimental medicine and biology, 2002, Volume: 507

    Topics: Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Kinetics; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Recombinant Proteins; Sulfonamides; Time Factors

2002
[Adverse effect-free analgesia. New COX-2 inhibitor is even more selective].
    MMW Fortschritte der Medizin, 2003, May-01, Volume: 145, Issue:18

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Pain; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Treatment Outcome

2003
Effects of rofecoxib, celecoxib, and parecoxib on anti-IgE-induced histamine release from human skin mast cells and basophils.
    Allergy, 2003, Volume: 58, Issue:10

    Topics: Antibodies, Anti-Idiotypic; Basophils; Celecoxib; Cyclooxygenase Inhibitors; Histamine Release; Humans; Isoxazoles; Lactones; Mast Cells; Pyrazoles; Skin; Sulfonamides; Sulfones

2003
Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines.
    Cancer biology & therapy, 2004, Volume: 3, Issue:1

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Glioblastoma; Humans; Indomethacin; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; Sulindac

2004
Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
    Journal of medicinal chemistry, 2004, Jan-29, Volume: 47, Issue:3

    Topics: Animals; Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Intraocular Pressure; Isoenzymes; Isoxazoles; Kinetics; Lactones; Models, Molecular; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Rabbits; Structure-Activity Relationship; Sulfonamides; Sulfones

2004
Coxibs and cardiovascular disease.
    The New England journal of medicine, 2004, Oct-21, Volume: 351, Issue:17

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Epoprostenol; Gastrointestinal Diseases; Humans; Isoenzymes; Isoxazoles; Lactones; Membrane Proteins; Naproxen; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk; Sulfonamides; Sulfones; Thromboxane A2; United States; United States Food and Drug Administration

2004
Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modification: comparison to sulfonamide COX-2 inhibitors and NSAIDs.
    Atherosclerosis, 2004, Volume: 177, Issue:2

    Topics: Animals; Antioxidants; Celecoxib; Cholesterol, LDL; Chromans; Cyclooxygenase Inhibitors; Diclofenac; Humans; Ibuprofen; Isoprostanes; Isoxazoles; Lactones; Meloxicam; Naproxen; Oxidation-Reduction; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles

2004
Arthritis medicines and cardiovascular events--"house of coxibs".
    JAMA, 2005, Jan-19, Volume: 293, Issue:3

    Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Humans; Isoxazoles; Pyrazoles; Sulfonamides; United States; United States Food and Drug Administration

2005
Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids.
    Biomedical chromatography : BMC, 2005, Volume: 19, Issue:5

    Topics: Butanones; Celecoxib; Chromatography, Liquid; Cyclooxygenase 2 Inhibitors; Humans; Isoxazoles; Lactones; Nabumetone; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Sulfonamides; Sulfones

2005
COX-2 inhibitors--lessons in drug safety.
    The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

    Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Publishing; Pyrazoles; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
COX-2 inhibitors--a lesson in unexpected problems.
    The New England journal of medicine, 2005, Mar-17, Volume: 352, Issue:11

    Topics: Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Gastrointestinal Hemorrhage; Humans; Isoxazoles; Lactones; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones

2005
Vioxx may go back on sale after scraping past FDA panel.
    Nature, 2005, Feb-24, Volume: 433, Issue:7028

    Topics: Celecoxib; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
    Science (New York, N.Y.), 2005, Feb-25, Volume: 307, Issue:5713

    Topics: Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Stroke; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
A painkiller is pulled from the market. So what do you do now?
    Heart advisor, 2004, Volume: 7, Issue:12

    Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Humans; Isoxazoles; Nonprescription Drugs; Pyrazoles; Sulfonamides

2004
Raising the safety bar--the FDA's coxib meeting.
    The New England journal of medicine, 2005, Mar-31, Volume: 352, Issue:13

    Topics: Advertising; Advisory Committees; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drug Labeling; Humans; Isoxazoles; Lactones; Product Surveillance, Postmarketing; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy?
    American journal of physiology. Regulatory, integrative and comparative physiology, 2005, Volume: 288, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase Inhibitors; Drug Design; Humans; Intramolecular Oxidoreductases; Isoxazoles; Lactones; Microsomes; Prostaglandin-E Synthases; Pyrazoles; Sulfonamides; Sulfones

2005
New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra).
    CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2005, May-10, Volume: 172, Issue:10

    Topics: Canada; Cardiovascular Diseases; Celecoxib; Clinical Trials as Topic; Contraindications; Cyclooxygenase Inhibitors; Decision Making; Drug Approval; Humans; Isoxazoles; Product Surveillance, Postmarketing; Pyrazoles; Risk Factors; Sulfonamides; United States; United States Food and Drug Administration

2005
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention.
    Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
Rescuing COX-2 inhibitors from the waste bin.
    Journal of the National Cancer Institute, 2005, Jun-01, Volume: 97, Issue:11

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Endothelial Cells; Humans; Isoxazoles; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A

2005
Simultaneous quantitation of etoricoxib, salicylic acid, valdecoxib, ketoprofen, nimesulide and celecoxib in plasma by high-performance liquid chromatography with UV detection.
    Biomedical chromatography : BMC, 2006, Volume: 20, Issue:1

    Topics: Animals; Celecoxib; Chromatography, High Pressure Liquid; Etoricoxib; Humans; Isoxazoles; Ketoprofen; Male; Pyrazoles; Pyridines; Rats; Rats, Wistar; Reproducibility of Results; Salicylic Acid; Spectrophotometry, Ultraviolet; Sulfonamides; Sulfones

2006
Regulatory paternalism in the market for drugs: lessons from Vioxx and Celebrex.
    Yale journal of health policy, law, and ethics, 2005,Summer, Volume: 5, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chromans; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug and Narcotic Control; Drug Industry; Humans; Hypoglycemic Agents; Isoxazoles; Lactones; Myocardial Infarction; Paternalism; Platelet Aggregation Inhibitors; Pyrazoles; Sulfonamides; Sulfones; Thiazolidinediones; Troglitazone; Truth Disclosure; United States; United States Food and Drug Administration; Vasodilator Agents

2005
How celecoxib could be safer, how valdecoxib might have been.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:9

    Topics: Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Drug Industry; Humans; Isoxazoles; Pyrazoles; Risk Assessment; Sulfonamides; United States; United States Food and Drug Administration

2005
The cyclooxygenase-2 inhibitor celecoxib is a potent inhibitor of human carbonic anhydrase II.
    Inflammation, 2004, Volume: 28, Issue:5

    Topics: Acetazolamide; Anti-Inflammatory Agents, Non-Steroidal; Carbonic Anhydrase II; Carbonic Anhydrase Inhibitors; Celecoxib; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Inhibitory Concentration 50; Isoxazoles; Pyrazoles; Structure-Activity Relationship; Sulfonamides

2004
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    Drug safety, 2005, Volume: 28, Issue:10

    Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Pyrazoles; Stevens-Johnson Syndrome; Sulfonamides; Sulfones

2005
Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II "selective" inhibitor celecoxib.
    Bioorganic & medicinal chemistry letters, 2006, Jan-15, Volume: 16, Issue:2

    Topics: Binding Sites; Carbonic Anhydrase Inhibitors; Carbonic Anhydrases; Celecoxib; Crystallography, X-Ray; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Drug Evaluation, Preclinical; Humans; Isoenzymes; Isoxazoles; Models, Molecular; Molecular Structure; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Topoisomerase II Inhibitors

2006
[Cyclooxygenase-2 inhibitors and the ethics of research].
    Medicina, 2005, Volume: 65, Issue:5

    Topics: Celecoxib; Cyclooxygenase Inhibitors; Drug Approval; Ethics, Research; Humans; Isoxazoles; Lactones; Pyrazoles; Sulfonamides; Sulfones

2005
Ocular adverse effects associated with cyclooxygenase-2 inhibitors.
    Archives of ophthalmology (Chicago, Ill. : 1960), 2006, Volume: 124, Issue:2

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Celecoxib; Conjunctivitis; Cyclooxygenase 2 Inhibitors; Etodolac; Humans; Isoxazoles; Lactones; Middle Aged; Pyrazoles; Sulfonamides; Sulfones; Vision Disorders

2006
Lessons to learn from the COX-2 saga. Yes, FDA reforms are needed. And marketing distorts how medications are used. But one moral to the story is that all drugs have risks.
    Harvard health letter, 2005, Volume: 30, Issue:5

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug-Related Side Effects and Adverse Reactions; Humans; Isoxazoles; Lactones; Marketing of Health Services; Naproxen; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2005
Reversible binding of celecoxib and valdecoxib with human serum albumin using fluorescence spectroscopic technique.
    Pharmacological research, 2006, Volume: 54, Issue:2

    Topics: Anilino Naphthalenesulfonates; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Fluorescent Dyes; Hydrogen-Ion Concentration; Isoxazoles; Molecular Structure; Protein Binding; Pyrazoles; Serum Albumin; Spectrometry, Fluorescence; Structure-Activity Relationship; Sulfonamides; Temperature; Thermodynamics

2006
The COX-2 inhibitors--an update.
    American heart journal, 2006, Volume: 152, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Labeling; Humans; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones; United States; United States Food and Drug Administration

2006
How specific are "target-specific" drugs? Celecoxib as a case in point.
    Molecular interventions, 2006, Volume: 6, Issue:4

    Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Isoxazoles; Lactones; Molecular Structure; Protein Binding; Pyrazoles; Sulfonamides; Sulfones

2006
[Cyclooxygenase inhibitors: a never ending story?].
    Giornale italiano di cardiologia (2006), 2006, Volume: 7, Issue:7

    Topics: Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Approval; Europe; Humans; Isoxazoles; Italy; Lactones; Liability, Legal; Prostaglandin-Endoperoxide Synthases; Protein Isoforms; Pyrazoles; Sulfonamides; Sulfones; Texas; United States; United States Food and Drug Administration

2006
Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen.
    Harvard heart letter : from Harvard Medical School, 2006, Volume: 17, Issue:2

    Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Gastrointestinal Diseases; Isoxazoles; Lactones; Pyrazoles; Risk Assessment; Sulfonamides; Sulfones

2006
Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
    Circulation, 2007, Jan-23, Volume: 115, Issue:3

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cardiovascular Diseases; Celecoxib; Cyclooxygenase Inhibitors; Humans; Isoxazoles; Lactones; Myocardial Infarction; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Risk Factors; Sulfonamides; Sulfones; Ventricular Remodeling

2007
Cyclooxygenase-2 inhibition increases gastric tone and delays gastric emptying in rats.
    Neurogastroenterology and motility, 2007, Volume: 19, Issue:3

    Topics: Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Gastric Emptying; Gastric Mucosa; Indomethacin; Isoxazoles; Ketorolac; Lactones; Male; Muscle, Smooth; Pyrazoles; Rats; Rats, Wistar; Stomach; Sulfonamides; Sulfones

2007
Coxibs: can this class of drugs survive?
    Vascular health and risk management, 2005, Volume: 1, Issue:1

    Topics: Arthritis; Cardiovascular Diseases; Celecoxib; Cyclooxygenase 2 Inhibitors; Etoricoxib; Evidence-Based Medicine; Half-Life; Humans; Isoxazoles; Lactones; Patient Selection; Pyrazoles; Pyridines; Sulfonamides; Sulfones

2005
Preliminary development of a responder index for chronic low back pain.
    The Journal of rheumatology, 2007, Volume: 34, Issue:6

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chronic Disease; Clinical Trials as Topic; Focus Groups; Health Status Indicators; Humans; International Cooperation; Isoxazoles; Low Back Pain; Outcome Assessment, Health Care; Pyrazoles; Reproducibility of Results; Sulfonamides

2007
Orthodontic tooth movement after different coxib therapies.
    European journal of orthodontics, 2007, Volume: 29, Issue:6

    Topics: Alveolar Process; Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cephalometry; Cyclooxygenase 2 Inhibitors; Gingiva; Isoxazoles; Lactones; Male; Molar; Orthodontic Wires; Pyrazoles; Rats; Rats, Wistar; Sulfonamides; Sulfones; Time Factors; Tooth Movement Techniques

2007
Use of cox-2 inhibitors in patients with retinal venous occlusive disease.
    Retina (Philadelphia, Pa.), 2008, Volume: 28, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Utilization; Female; Humans; Isoxazoles; Lactones; Male; Middle Aged; Prevalence; Pyrazoles; Retinal Vein Occlusion; Retrospective Studies; Sulfonamides; Sulfones

2008
Crunch time for peer review in lawsuit.
    Nature, 2008, Mar-06, Volume: 452, Issue:7183

    Topics: Celecoxib; Confidentiality; Drug Industry; Humans; Isoxazoles; Peer Review, Research; Periodicals as Topic; Pyrazoles; Sulfonamides; United States

2008
Preserving confidentiality in the peer review process.
    JAMA, 2008, Apr-23, Volume: 299, Issue:16

    Topics: Advertising; Celecoxib; Confidentiality; Cyclooxygenase 2 Inhibitors; Disclosure; Drug Industry; Isoxazoles; Liability, Legal; Peer Review, Research; Pyrazoles; Sulfonamides; United States

2008
Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis.
    Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:6

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cohort Studies; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Follow-Up Studies; Humans; Isoxazoles; Lactones; Male; Middle Aged; Myocardial Infarction; Naproxen; Osteoarthritis; Proportional Hazards Models; Pyrazoles; Retrospective Studies; Risk Factors; Stroke; Sulfonamides; Sulfones; United States

2008
The effect of selective cyclooxygenase-2 inhibitor on human osteoclast precursors to influence osteoclastogenesis in vitro.
    Modern rheumatology, 2009, Volume: 19, Issue:2

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Resorption; Celecoxib; Cell Growth Processes; Cell Survival; Cells, Cultured; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Humans; Indomethacin; Isoxazoles; Macrophage Colony-Stimulating Factor; Osteoclasts; Pyrazoles; RANK Ligand; Stem Cells; Sulfonamides; Time Factors

2009
Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk.
    Breast (Edinburgh, Scotland), 2011, Volume: 20, Issue:1

    Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; Female; Humans; Incidence; Isoxazoles; Lactones; Logistic Models; Middle Aged; Odds Ratio; Pyrazoles; Risk; Sulfonamides; Sulfones

2011
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
    Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:5

    Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis

2010
Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Contact dermatitis, 2012, Volume: 66, Issue:2

    Topics: Aged; Arm; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Eruptions; Etoricoxib; Female; Humans; Isoxazoles; Leg Dermatoses; Low Back Pain; Patch Tests; Pyrazoles; Pyridines; Sulfonamides; Sulfones

2012
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
    Toxicology in vitro : an international journal published in association with BIBRA, 2016, Volume: 32

    Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones

2016
The efficacy of a multimodal analgesia protocol in preventing heterotopic ossification after acetabular fractures surgery.
    International journal of clinical pharmacy, 2017, Volume: 39, Issue:4

    Topics: Acetabulum; Adult; Aged; Analgesia; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Isoxazoles; Male; Middle Aged; Ossification, Heterotopic; Pain Management; Pain, Postoperative; Retrospective Studies; Treatment Outcome; Young Adult

2017
Radiosynthesis and in vivo evaluation of [
    Bioorganic & medicinal chemistry letters, 2018, 08-01, Volume: 28, Issue:14

    Topics: Animals; Brain; Carbon Radioisotopes; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Isoxazoles; Male; Molecular Structure; Papio; Positron-Emission Tomography; Rats; Rats, Sprague-Dawley; Sulfonamides

2018
Copper-Catalyzed Reductive Ring-Cleavage of Isoxazoles: Synthesis of Fluoroalkylated Enaminones and Application for the Preparation of Celecoxib, Deracoxib, and Mavacoxib.
    The Journal of organic chemistry, 2021, 03-19, Volume: 86, Issue:6

    Topics: Catalysis; Celecoxib; Copper; Isoxazoles; Pyrazoles; Sulfonamides

2021
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
    BMC cancer, 2021, May-03, Volume: 21, Issue:1

    Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway

2021
Perioperative Outcomes of Patients Who Were Not Candidates for Additional Nonsteroidal Anti-inflammatory Drugs in a Multimodal Pain Control Regimen for Total Knee Arthroplasty.
    Clinics in orthopedic surgery, 2021, Volume: 13, Issue:2

    Topics: Aged; Analgesia, Patient-Controlled; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Knee; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Humans; Isoxazoles; Male; Middle Aged; Morphine; Pain Management; Pain Measurement; Pain, Postoperative; Retrospective Studies

2021